Trial Profile
Multicenter study of a single arm to evaluate the safety of eribulin in 3rd line chemotherapy for patients with HER2-negative metastatic or locally advanced previously treated with anthracyclines and taxanes: Onsite Study [Estudio multicéntrico de un sólo brazo para evaluar la seguridad de Eribulina en 3? línea de quimioterapia para pacientes con cáncer de mama HER2 negativo metastásico o locamente avanzado tratado previamente con taxanos y antraciclina: Estudio OnSITE]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Nov 2016
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Acronyms OnSITE
- Sponsors Eisai Co Ltd
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 29 Sep 2016 According to Eisai media release, subanalyses from this study will be presented at the European Society for Medical Oncology (ESMO) Congress.
- 11 May 2016 Status changed from active, no longer recruiting to completed.